MDMA

Phase 2Recruiting

4 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Post-Traumatic Stress Disorder

Conditions

Post-Traumatic Stress Disorder, Adjustment Disorders

Trial Timeline

Apr 1, 2026 → Jun 1, 2028

NCT ID

NCT05455996

About MDMA

MDMA is a phase 2 stage product being developed by Nautilus Biotechnology for Post-Traumatic Stress Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05455996. Target conditions include Post-Traumatic Stress Disorder, Adjustment Disorders.

What happened to similar drugs?

3 of 7 similar drugs in Post-Traumatic Stress Disorder were approved

Approved (3) Terminated (3) Active (1)

✅Galcanezumab-GnlmEli LillyApproved

🔄Quetiapine Fumarate + quetiapine fumarate placeboAstraZenecaPhase 3

❌Zoloft (Sertraline)PfizerPhase 3

❌Levetiracetam + PlaceboUCBPhase 3

❌Placebo + BrexpiprazoleLundbeckPhase 3

✅AbobotulinumtoxinA + Normal salineIpsenApproved

✅Tramadol + PlaceboBrain BiotechApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05455996	Phase 2	Recruiting	Apr 1, 2026	Jun 1, 2028	Post-Traumatic Stress Disorder

Competing Products

16 competing products in Post-Traumatic Stress Disorder

See all competitors

Product	Company	Stage	Hype Score
Galcanezumab-Gnlm	Eli Lilly	Approved	43
Quetiapine Fumarate + quetiapine fumarate placebo	AstraZeneca	Phase 3	40
Rizatriptan + Placebo	Merck	Pre-clinical	18
AMG 334	Novartis	Phase 2	35
Balovaptan + Placebo	Roche	Phase 2	35
Erenumab	Amgen	Phase 2	35
PF-04457845 + Placebo	Pfizer	Phase 2	27
Zoloft (Sertraline)	Pfizer	Phase 3	32
Levetiracetam + Placebo	UCB	Phase 3	32
levetiracetam + Placebo + Levetriracetam	UCB	Phase 2/3	38
Placebo + Brexpiprazole	Lundbeck	Phase 3	29
Brexpiprazole + Sertraline + Brexpiprazole Matching Placebo + Sertraline Matching Placebo	Lundbeck	Phase 2	32
AbobotulinumtoxinA + Normal saline	Ipsen	Approved	40
Nabiximols + Placebo	Jazz Pharmaceuticals	Phase 2/3	27
60 mg PRAX-114 or 40 mg PRAX-114 + Placebo + 40 mg PRAX-114	Praxis Precision Medicines	Phase 2	24
Tramadol + Placebo	Brain Biotech	Approved	33